ArticleFacts, views & vision in ObGyn2011
Postpartum breast cancer behaves differently.
Article in Facts, views & vision in ObGyn, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.Cancer reports (Hoboken, N.J.) · 2026Observational
- Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.Molecular cancer · 2024Article
- Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants.JAMA network open · 2024Article
- Clinical characteristics and prognosis of postpartum breast cancer.Breast cancer research and treatment · 2023Article
- Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Gestational Breast Cancer - a Review of Outcomes, Pathophysiology, and Model Systems.Journal of mammary gland biology and neoplasia · 2023Review
- A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature.Annals of translational medicine · 2022Article
- Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2021Review
- Article
- LC3-Associated Phagocytosis (LAP): A Potentially Influential Mediator of Efferocytosis-Related Tumor Progression and Aggressiveness.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPrevious studies suggest a worse prognosis for postpartum breast cancer (PPBC) diagnosed within the first 12 months following delivery. We investigated this hypothesis in our setting through a retrospective pilot study.
methodsA retrospective multicentre paired case-control study of breast cancer patients diagnosed under age 45 from the UZ Leuven database or affiliated centres. We compared disease outcome of women with a PPBC and those without a pregnancy associated breast cancer (PABC). They were matched for the following prognostic markers: age at diagnosis, tumour type, characteristics and stage. Kaplan-Meier statistics were applied for overall and disease free survival.
results53 PPBC cases were matched with 103 controls. All PPBC patients were diagnosed with an invasive ductal carcinoma. Axillary lymph nodes were involved in 56.6% of cases and 13% were primary metastasized at diagnosis. A third was triple-negative and another third was HER-2-positive.The 5-year overall survival was 60% and 84% respec-tively for PPBC cases and control group. 5-year disease free survival was respectively 53% and 68%.
conclusionsWe confirm that postpartum breast cancer behaves more aggressively than the matched non-PABC group. Longer follow-up and extension of the study group are necessary to confirm these findings.
Indexed as
Identifiers
24753864PMC3991453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.